UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000034466
Receipt number R000039308
Scientific Title Effects of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) on the lung function in Japanese patients with ssthma
Date of disclosure of the study information 2018/10/12
Last modified on 2019/04/18 14:15:03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) on the lung function in Japanese patients with ssthma

Acronym

Lung function change by FF/VI

Scientific Title

Effects of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) on the lung function in Japanese patients with ssthma

Scientific Title:Acronym

Lung function change by FF/VI

Region

Japan


Condition

Condition

Asthma

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The Japanese drug use system allowed the "once-daily use" of inhaled corticosteroid (fluticasone furoate) combined with a long acting beta-2 agonist (vilanterol) against asthma for the first time in 2013. We investigated the real-world efficacy and problems of this drug.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of lung function test data

Key secondary outcomes

Questions on the control of asthma, side effects, and preference of drug are asked.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Prior treatments of asthma (twice-daily use of inhaled steroids with or without long-acting beta-2 agonists) were changed to once-daily use of fluticasone furoate (FF)/vilanterol(VI) (200 microgram/25 microgram). Subjects were evaluated by lung function tests prior to, and 2-3 months after, the initiation of FF/VI

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with astmam had to be already satisfied with their current treatment with regular maintenance inhalation therapy with inhaled corticosteroid (ICS) alone or ICS combined with a long acting beata-2 agonist.

Key exclusion criteria

None

Target sample size

150


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akira Umeda

Organization

International University of Health and Welfare Shioya Hospital

Division name

Department of Respiratory Medicine

Zip code


Address

Tomita 77, Yaita-City, Tochigi 329-2145, Japan

TEL

0287-44-1155

Email

umeda@iuhw.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masato Takahashi

Organization

International University of Health and Welfare Hospital

Division name

Ethics Committee

Zip code


Address

Iguchi 537-3, Nasushiobara-City, Tochigi 329-2763, Japan

TEL

0287-39-3060

Homepage URL


Email

masa-takahashi@iuhw.ac.jp


Sponsor or person

Institute

International University of Health and Welfare

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 10 Month 12 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 09 Month 01 Day

Date of IRB

2014 Year 08 Month 22 Day

Anticipated trial start date

2014 Year 09 Month 24 Day

Last follow-up date

2019 Year 04 Month 15 Day

Date of closure to data entry

2019 Year 04 Month 15 Day

Date trial data considered complete

2019 Year 04 Month 15 Day

Date analysis concluded

2019 Year 04 Month 15 Day


Other

Other related information



Management information

Registered date

2018 Year 10 Month 12 Day

Last modified on

2019 Year 04 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039308


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name